Insulet Corporation (PODD)
- Previous Close
167.27 - Open
168.18 - Bid 166.89 x 100
- Ask 167.28 x 100
- Day's Range
165.85 - 169.34 - 52 Week Range
125.82 - 335.91 - Volume
635,101 - Avg. Volume
869,485 - Market Cap (intraday)
11.711B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
56.89 - EPS (TTM)
2.94 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
236.83
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
www.insulet.comRecent News: PODD
Performance Overview: PODD
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PODD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PODD
Valuation Measures
Market Cap
11.71B
Enterprise Value
12.42B
Trailing P/E
56.89
Forward P/E
58.48
PEG Ratio (5yr expected)
3.00
Price/Sales (ttm)
7.26
Price/Book (mrq)
15.99
Enterprise Value/Revenue
7.32
Enterprise Value/EBITDA
38.39
Financial Highlights
Profitability and Income Statement
Profit Margin
12.16%
Return on Assets (ttm)
6.09%
Return on Equity (ttm)
34.13%
Revenue (ttm)
1.7B
Net Income Avi to Common (ttm)
206.3M
Diluted EPS (ttm)
2.94
Balance Sheet and Cash Flow
Total Cash (mrq)
704.2M
Total Debt/Equity (mrq)
197.73%
Levered Free Cash Flow (ttm)
-38.05M
Research Analysis: PODD
Company Insights: PODD
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: PODD
Analyst Report: Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
RatingPrice TargetAnalyst Report: Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
RatingPrice TargetAnalyst Report: Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
RatingPrice TargetAnalyst Report: Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
RatingPrice Target